Drug Insights

Accessing Midodrine Information on Synapse: A Step-by-Step Approach

27 March 2024
2 min read

Midodrine, a diminutive molecule of therapeutic nature, exhibits its therapeutic effect through its agonistic action upon the α-adrenergic receptor. This pharmacological agent is commonly utilized to ameliorate hypotension, particularly orthostatic hypotension, via its vasoconstrictive actions that lead to a rise in blood pressure. Midodrine obtained approval from the Food and Drug Administration (FDA) in March of the year 1987, and its development can be attributed to the eminent pharmaceutical company, Shire. As an agonist for the α-adrenergic receptor, Midodrine engenders a robust stimulatory response of the sympathetic nervous system, which in turn orchestrates the regulation of both heart rate and blood pressure. By virtue of its multifarious actions, Midodrine has proven efficacy in addressing various maladies stemming from hypotension, encompassing autonomic dysfunction and chronic fatigue syndrome. Click on the image below to begin the exploration journey of Midodrine through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Mission Therapeutics Launches Key Study on MTX325 for Parkinson’s Disease Progression
Latest Hotspot
3 min read
Mission Therapeutics Launches Key Study on MTX325 for Parkinson’s Disease Progression
27 March 2024
Mission Therapeutics has initiated a pivotal study on MTX325, which could potentially alter the progression of Parkinson’s Disease.
Read →
Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
Hot Spotlight
8 min read
Sumitomo Pharma Renews Collaborative Development Agreement with Otsuka Pharmaceutical for Multiple Psychiatric Disorder Treatments
27 March 2024
Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.
Read →
Italfarmaco's Duvyzat™ Approved by FDA for Duchenne Muscular Dystrophy
Latest Hotspot
3 min read
Italfarmaco's Duvyzat™ Approved by FDA for Duchenne Muscular Dystrophy
27 March 2024
FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.
Read →
Maximize Your Synapse Use: Your Guide to Searching Indomethacin
Drug Insights
2 min read
Maximize Your Synapse Use: Your Guide to Searching Indomethacin
27 March 2024
Indomethacin is a small NSAID that blocks the COX enzyme to reduce inflammation and pain.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.